In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (NEJM)
Diabetes News
Tag: closed-loop
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump (NEJM)
Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial
Closed-loop insulin delivery is an effective treatment option to improve glycaemic control in patients receiving nutritional support in hospital (The Lancet Diabetes & Endocrinology)
Participants’ Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings
While participants reported substantial benefits to using the closed loop during the day, they also identified ways in which the technology could be refined and education and training tailored to optimize effective use. Our findings suggest that mainstreaming this technology will not necessarily lead to increased demands on clinical staff (Diabetes Technology and Therapeutics)
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes (The Lancet)
Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care
Among inpatients with type 2 diabetes receiving noncritical care, the use of an automated, closed-loop insulin-delivery system resulted in significantly better glycemic control than conventional subcutaneous insulin therapy, without a higher risk of hypoglycemia (NEJM)
Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care
Among inpatients with type 2 diabetes receiving noncritical care, the use of an automated, closed-loop insulin-delivery system resulted in significantly better glycemic control than conventional subcutaneous insulin therapy, without a higher risk of hypoglycemia (NEJM)
Faster insulin action is associated with improved glycemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes
Faster insulin action is associated with improved glycemic control during closed-loop insulin delivery and sensor-augmented pump therapy (Diabetes, Obesity and Metabolism)
Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial
Closed-loop insulin delivery without meal-time boluses is effective and safe in insulin-treated adults with type 2 diabetes in the general ward (The Lancet Diabetes & Endocrinology)
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
Hybrid closed-loop automated insulin delivery was associated with few serious or device-related adverse events in patients with type 1 diabetes (JAMA)
Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes
Overnight closed-loop therapy resulted in better glucose control than sensor-augmented pump therapy in pregnant women with type 1 diabetes. Women receiving day-and-night closed-loop therapy maintained glycemic control during a high proportion of the time in a period that encompassed antenatal hospital admission, labor, and delivery (NEJM)
2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions
Our results support the use of AP at home as a safe and beneficial option for patients with type 1 diabetes. The HbA1c results are encouraging but preliminary (Lancet)
Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial
Twenty five percent reduction of prandial boluses during closed-loop maintains comparable glucose control in adolescents with T1D whilst lowering overall plasma insulin levels. It remains unclear whether closed-loop therapy with 25% reduction of prandial boluses will prevent postprandial hypoglycemia (Diabetes, Obesity and Metabolism)
Glycosmedia is also available as an App: